EUVIMEDEUVIMED entdecken
Crossref

Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system

Lu Lyu, Sainan Bian, Kai Guan iD, Bin Zhao

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Lu Lyu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Cent…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Eosinophils, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophil‐induced adverse events (Eo‐irAEs) have been observed in patients treated with programmed cell death 1/ligand 1 (PD‐1/PD‐L1) inhibitors. Surprisingly, the clinical features and outcomes of Eo‐irAEs induced by PD‐1/PD‐L1 inhibitors have not yet been elucidated. This study investigated the characteristics of and risk factors for Eo‐irAEs induced by PD‐1/PD‐L1 inhibitors. We extracted data on Eo‐irAEs related to PD‐1/PD‐L1 inhibitors from the FDA Adverse Event Reporting System (FAERS) from 2015 to 2023. Disproportionality and Bayesian analyses were applied for data mining and analysis. A total of 430 Eo‐irAEs induced by PD‐1/PD‐L1 inhibitors were included in this study. Older male patients were found to be at a high risk of developing Eo‐irAEs. Cemiplimab (ROR 2.66 [1.38, 5.13]), nivolumab (ROR 1.82 [1.61, 2.05]), and pembrolizumab (ROR 1.35 [1.13, 1.62]) showed stronger signals than the other drugs. Cemiplimab showed higher signals for Eo‐irAEs than other PD‐1/PD‐L1 inhibitors, with an information component (IC) of 1.41 (IC 0.25:0.73). Patients experienced Eo‐irAEs within the first 100 days, with a median onset time of 56 (interquartile range: 17.0–169.0) days. Eo‐irAEs were more likely to occur in patients with lung ( n = 147, 34.83%) and skin tumors ( n = 145, 34.36%). Eosinophilia ( n = 193, 44.88%), drug reactions with eosinophilia and systemic symptoms (DRESS) ( n = 98, 22.79%), and eosinophilic fasciitis ( n = 69, 16.05%) were the most common adverse events. Eo‐irAEs that were life‐threatening or resulted in death comprised 5.15% ( n = 21) and 5.39% ( n = 22) of the patients. PD‐1/PD‐L1 inhibitors used across a broad spectrum of cancers are associated with an increased risk of Eo‐irAEs, which tend to occur early. Although these complications are rare, clinicians using PD‐1/PD‐L1 inhibitors should be aware of and monitor these potentially serious adverse events related to Eo‐irAEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsEosinophilsB7-H1 AntigenImmune Checkpoint InhibitorsEosinophiliaDrug-Related Side Effects and Adverse ReactionsHumansMaleUnited StatesUnited States Food and Drug AdministrationFemaleAgedMiddle AgedAdultProgrammed Cell Death 1 ReceptorBayes TheoremRisk FactorsAntibodies, Monoclonal, HumanizedAged, 80 and over

Stichwörter der Autor:innen

FAERSPD‐1/PD‐L1 inhibitorscancereosinophil‐induced adverse eventsimmune‐related adverse events

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedPDCD1 protein, humanpembrolizumab

Autor:innen und Institutionen

  • Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical Col…
  • Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
  • State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
  • School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, China.

ORCID-Profile: Kai Guan

Förderung

  • National Natural Science Foundation of China
  • Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences

Zitieren

APA

Lyu, L., Bian, S., Guan, K., & Zhao, B. (2025). Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. International Journal of Cancer. https://doi.org/10.1002/ijc.35398

Vancouver

Lyu L, Bian S, Guan K, Zhao B. Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. International Journal of Cancer. 2025. doi:10.1002/ijc.35398

BibTeX
@article{Lyu2025,
  author = {Lyu, Lu and Bian, Sainan and Guan, Kai and Zhao, Bin},
  title = {Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35398}
}
Kostenlos starten →